LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.

Abstract excerpt

In the combined use of bronchodilators of different classes, ie, long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), bronchodilation is obtained both directly, through LABA-mediated stimulation of β2-adrenergic receptors, and indirectly, through LAMA-mediated inhibition of acetylcholine action at muscarinic receptors. The clinical trial data for LABAs/LAMAs in the treatment of chronic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Administration, Inhalation
• Share to Adrenal Cortex Hormones
• Share to Adrenergic beta-2 Receptor Agonists